bipolar II disorder; bipolar depression
Jump to navigation
Jump to search
Clinical manifestations
- both a hypomanic episode & a major depressive episode
- no manic episodes
Management
- see bipolar disorder
- bright light mid-day (noon) may improve depression[2]
- aspirin 81 mg QD may be of benefit (NNT=4)[3]
- minocycline alone or in combination with aspirin may or may not be of benefit[3]
- CoQ10 may improve symptoms of depression[4]
- psylocybin 25 mg PO single dose[6]
- lumateperone (Caplyta) FDA-approved to treat with depressive episodes associated with bipolar I disorder & bipolar II disorder as monotherapy or adjunctive therapy with lithium or valproate[5]
More general terms
References
- ↑ NEJM Knowledge+ Question of the Week. Aug 15, 2017 https://knowledgeplus.nejm.org/question-of-week/1288/
- ↑ 2.0 2.1 Sit DK, McGowan J, Wiltrout C et al. Adjunctive bright light therapy for bipolar depression: A randomized double-blind placebo-controlled trial. Am J Psychiatry 2017 Oct 3; <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28969438 <Internet> http://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2017.16101200
- ↑ 3.0 3.1 3.2 Savitz JB, Teague TK, Misaki M et al. Treatment of bipolar depression with minocycline and/or aspirin: An adaptive, 2 2 double-blind, randomized, placebo-controlled, phase IIA clinical trial. Transl Psychiatry. 2018 Jan 24;8(1):27 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29362444 Free PMC Article
- ↑ 4.0 4.1 Mehrpooya M et al. Evaluating the effect of coenzyme Q10 augmentation on treatment of bipolar depression: A double-blind controlled clinical trial. J Clin Psychopharmacol 2018 Oct; 38:460. PMID: https://www.ncbi.nlm.nih.gov/pubmed/30106880
- ↑ 5.0 5.1 Brooks M FDA Grants New Indication to Lumateperone (Caplyta) for Bipolar Depression. Medscape. December 20, 2021 https://www.medscape.com/viewarticle/965134
- ↑ 6.0 6.1 Aaronson ST, van der Vaart A, Miller T et al Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes. A Nonrandomized Controlled Trial. JAMA Psychiatry. Published online December 6, 2023 PMID: https://www.ncbi.nlm.nih.gov/pubmed/38055270 https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2812443
Yaden DB, Gukasyan N, Nayak SM et al Psilocybin in Bipolar II Study Provides Preliminary Data on Safety. JAMA Psychiatry. Published online December 6, 2023. PMID: https://www.ncbi.nlm.nih.gov/pubmed/38055240 https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2812445